BioNTech 以 $800M 收购 Biotheus 以扩大癌症治疗，增加了抗体 BNT327/PM8002。 BioNTech buys Biotheus for $800M to expand cancer treatments, adding antibody BNT327/PM8002.
BioNTech 已同意以 8 亿美元的价格收购 Biotheus，以增强其癌症治疗产品组合，获得前景广阔的双特异性抗体 BNT327/PM8002 的全部权利。 BioNTech has agreed to acquire Biotheus for $800 million to enhance its cancer treatment portfolio, gaining full rights to BNT327/PM8002, a promising bispecific antibody. 该交易将于 2025 年初完成，包括高达 1.5 亿美元的潜在额外付款，并将扩大 BioNTech 的研究和制造能力，尤其是在中国。 The deal, set to close in early 2025, includes potential additional payments of up to $150 million and will expand BioNTech's research and manufacturing capabilities, particularly in China. BNT327/PM8002 的多项临床试验计划于 2024 年和 2025 年进行。 Multiple clinical trials for BNT327/PM8002 are planned for 2024 and 2025.